| SPYRE THERAPEUTICS INC. |
| USA |
| Gesundheit |
| US00773J2024 / A3D4LY |
| 3920 (Frankfurt) / SYRE (NASDAQ) |
| FRA:3920, ETR:3920, 3920:GR, NASDAQ:SYRE |
| - |
| https://spyre.com/ |
|
Spyre Therapeutics Inc. operates as a biopharmaceu..
>Volltext.. |
| 1548.28 Mio. EUR |
| 1134.84 Mio. EUR |
| - |
| -194.19 Mio. EUR |
| -110.85 Mio. EUR |
| -1.89 EUR |
| - |
| 56.35 Mio. EUR |
| -140.92 Mio. EUR |
| 10.51 |
| - |
| -264.01% |
| - |
| - |
| - |
| - |
| SPYRE THERAPEUTICS, SPYRE THERAPEUTIC |
| 06.11.25 |
|
||||
|
||||
|
||||
|
||||
|